Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study.
DAA
HCV chronic hepatitis
HCV failure
HCV infection
HCV treatment
Interferon-free
PWID
SVR
antiviral therapy
drug users
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
30 Dec 2020
30 Dec 2020
Historique:
received:
22
11
2020
revised:
13
12
2020
accepted:
26
12
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
6
1
2021
Statut:
epublish
Résumé
We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate. Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy ( Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs).
METHODS
METHODS
We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID treated with DAAs. The primary outcome evaluated was the sustained virological response (SVR12) rate.
RESULTS
RESULTS
Five hundred and twenty HCV-infected PWID treated with all-oral DAA-based regimens were enrolled; a total of 168 (32.3%) patients presented genotype 1a, 109 (21.0%) genotype 1b, and 174 (33.5%) genotype 3; a total 152 of the 520 subjects (29.2%) were cirrhotics; a total 118 (22.7%) and 373 (71.7%) were treated with DAA regimens of second and third generation, respectively; a total 169 (33.6%) patients were receiving an opioid agonist at the start of antiviral therapy. Only 11 subjects (2.1%) did not show an SVR12. A significant correlation was found between treatment with opioid substitution therapy (
CONCLUSIONS
CONCLUSIONS
Treatment with DAAs led to a high SVR12 rate (97.9%) in a large cohort of HCV-infected PWID. The only predictor of viral failure found in our analysis was treatment with first- and second-generation DAA.
Identifiants
pubmed: 33396802
pii: life11010017
doi: 10.3390/life11010017
pmc: PMC7824069
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Felllowship program
ID : 2018
Références
J Hepatol. 2019 Jan;70(1):33-39
pubmed: 30367897
Hepatology. 1996 Aug;24(2):289-93
pubmed: 8690394
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
Int J Drug Policy. 2018 Dec;62:74-77
pubmed: 30368101
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
J Med Virol. 2018 May;90(5):942-950
pubmed: 29315640
J Viral Hepat. 2020 Dec;27(12):1437-1443
pubmed: 32810330
Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92
pubmed: 25895822
Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248
pubmed: 30430131
Int J Drug Policy. 2019 Apr;66:73-79
pubmed: 30735896
Antivir Ther. 2018;23(7):605-609
pubmed: 29504510
Subst Use Misuse. 2016 Jul 28;51(9):1218-23
pubmed: 27219274
Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):641-651
pubmed: 28831184
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Int J Drug Policy. 2018 Dec;62:94-103
pubmed: 30384028
Ann Intern Med. 2016 Nov 1;165(9):625-634
pubmed: 27537841
J Hepatol. 2018 Mar;68(3):402-411
pubmed: 29080808
Lancet. 2019 Oct 19;394(10207):1451-1466
pubmed: 31631857
Clin Infect Dis. 2020 Oct 23;71(7):e115-e124
pubmed: 31677262
Ann Intern Med. 2015 Aug 4;163(3):215-23
pubmed: 26120969
Liver Int. 2019 Oct;39(10):1852-1859
pubmed: 31175707
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767
pubmed: 30245064
J Hepatol. 2019 Jul;71(1):45-51
pubmed: 30853642
Hepatology. 2016 Apr;63(4):1090-101
pubmed: 26390137
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Hepatol. 2015 Aug;63(2):364-9
pubmed: 25839406
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133
pubmed: 28986139
J Viral Hepat. 2014 Mar;21(3):198-207
pubmed: 24438681
Addiction. 2018 May;113(5):868-882
pubmed: 29359361